|
1 |
Albi grade enables risk stratification for bleeding events and refines prognostic prediction in advanced HCC following atezolizumab and bevacizumab
Stefanini, Bernardo. - Freiburg : Universität, 2025
|
|
|
|
2 |
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Scheiner, Bernhard. - Freiburg : Universität, 2025
|
|
|
3 |
Ketone Monoester Supplementation Effects on a Comprehensive Cognitive Test Battery Following Non-Exhaustive Exercise
Enthalten in Journal of cognitive enhancement 26.12.2025: 1-11
|
|
|
|
4 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Celsa, Ciro. - Freiburg : Universität, 2023
|
|
|
5 |
Contemporary challenges in education
Münster : Waxmann, 2023
|
|
|
|
6 |
One Health assessment of persistent organic chemicals and PFAS for consumption of restored anadromous fish
Enthalten in Journal of exposure science & environmental epidemiology 15.12.2023: 1-10
|
|
|
|
7 |
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study
D’Alessio, Antonio. - Freiburg : Universität, 2022
|
|
|
|
8 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Fulgenzi, Claudia Angela Maria. - Freiburg : Universität, 2022
|
|
|
|
9 |
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Enthalten in Liver cancer Bd. 11, 2022, Nr. 4: 354-367. 14 S.
|
|
|
|
10 |
Deserteur
Delano, Jamie. - Mannheim : Dantes Verlag, Mai 2021, Erste Auflage
|
|
Administration
